IN8bio, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.78
- 52-Week Range
- $0.72 – $2.73
- Market Cap
- $8.35M
- P/E (TTM)
- —
- EPS (TTM)
- -1.00
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.54
- PEG Ratio
- —
- Return on Equity
- -141.83%
- Return on Assets
- -70.34%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 5.78
- Debt/Equity
- 0.19
- Total Debt
- $2.75M
- Free Cash Flow
- $-7.93M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-2.79M
Market Snapshot
About
IN8bio, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer treatment. The company's innovative approach focuses on harnessing the unique properties of gamma-delta T cells, which can recognize and kill cancer cells without requiring HLA matching. IN8bio's lead programs target both hematological malignancies and solid tumors using allogeneic (off-the-shelf) gamma-delta T cell products. The company's technology platform aims to deliver more accessible and affordable cell therapies with reduced risk of graft-versus-host disease and improved manufacturing scalability.